AMRI has completed the acquisition of Oso Biopharmaceuticals Manufacturing, a former portfolio company of Altaris Capital Partners, LLC.

OsoBio is a manufacturer of injectable drug products and its expertise in large-scale commercial production is complementary to AMRI's early-stage drug product manufacturing capabilities. The acquisition enables AMRI to provide sterile fill/finish services from Phase I development to commercial supply.

OsoBio is located in Albuquerque, New Mexico. Its  core capabilities include liquid fill and lyophilized products, highly potent compounds, cytotoxics, proteins and peptides, monoclonal antibodies, vaccines, liposomal suspensions, and controlled substances. The company has provided manufacturing support for more than 250 unique products, and its development pipeline, which includes multiple late-stage products, is expected to be an important contributor for future growth.

Total consideration paid was $110 million. AMRI financed the transaction with cash on hand.

Source: AMRI